Aktuella utlysningar, vecka 33, 2022
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anslag
Forskningstjänster - Stiftelsen Promobilia
Stiftelsen utlyser anslag till forskningstjänster inom ämnesområdet funktionshinder. Med begreppet funktionshinder avses fysisk och annan påverkan på funktion hos människa. Utveckling av hjälpmedel för att underlätta för funktionshindrade ingår i forskningsområdet. Utlysningen gäller två doktorandtjänster och två postdoktorstjänster båda med anslagstid om 2 år.
Closing date: 12 September 2022
Forskningsanslag – Cancer- och Allergifonden
Stöder vetenskaplig forskning om cancer- och allergisjukdomar. Maximalt belopp som kan sökas är 500 000 kronor och ansökan får endast omfatta ett år. En förutsättning för att ansökan ska behandlas är att huvudsökanden har kontrakt på förordnande som sträcker sig under hela 2023. De kriterier som bedöms är bland annat forskningsprojektets originalitet, vetenskaplig skicklighet, relevans till cancer och/eller allergi och genomförbarhet. Cancer-och Allergifondens forskningsanslag får inte användas till regelrätta djurförsök.
Closing date: 15 September 2022
Project grant for research into pandemics and their effects on society and public health – VR
This project grant is aimed at supporting research into pandemics and their effects on society and public health. The grant period is 1-3 years with a grant amount between 400 000 SEK – 1700000 SEK per year.
Please note that you can apply for this grant even if you submitted an application for a project grant under one of the major calls this spring. However, you will not be awarded several grants if the applications relate to the same project concept.
Closing date: 20 September 2022
Mobility Grants for Internationalisation - STINT
The aim of the Mobility Grants for Internationalisation programme is to strengthen Swedish research and higher education by developing and establishing international partnerships. The programme supports projects of high scientific quality which are clearly contributing to the activities of participating educational establishments. Projects may last for up to three years. Applicants should be employed by and active at a university in Sweden and have obtained their PhD. The proposed project must encompass at least one Swedish and at least one foreign party. The principal collaborating party shall be outside the EU/EFTA and UK. Applicants may have on-going projects in the Initiation Grants programme, but otherwise there must not be any on-going STINT projects.
Closing date: 26 September 2022
Forskningsanslag – Spädbarnsfonden
Spädbarnsfonden utlyser en gång per år medel för stöd till forskning med syfte att förebygga att barn dör före födelsen eller under spädbarnsperioden. Forskningen kan även handla om att förbättra bemötandet av drabbade föräldrar och närstående. Anslag kan sökas för biomedicinsk forskning, inom fostermedicin och nyföddhetsvård, och för omvårdnads- och vårdvetenskaplig samt psykosocial forskning. Medel kan sökas av disputerade forskare samt registrerade doktorander.
Closing date: 30 September 2022
Forskningsanslag – Reumatikerförbundet
Reumatikerförbundet välkomnar ansökningar för projekt inom reumatiska sjukdomar samt långvarig generaliserad smärta till exempel, fibromyalgi. Grundforskning med reumatologisk frågeställning och som är relevant för och kan gynna patienter ingår även inom ramen för Reumatikerförbundets anslag.
Closing date: 30 September 2022
Research grants - The Swedish Childhood Cancer Fund
The Swedish Childhood Cancer Fund finances childhood cancer research in Sweden, and also provides financial support to the development of new treatment methods and continuing education in the field of childhood cancer.
Open calls:
• Project grants for childhood cancer research
• Clinical project grants for childhood cancer research
• Medical technology
Closing date: 9 September 2022
• Travel grants
• Symposia
• PhD courses
• Methodological studies and educational courses
• Guest lecturer
Closing date: 15 September 2022
• Co-financing of EU projects
• Planning grants
Closing date: 23 September 2022
• Start-up grants
Closing date: open for applications all year round
Forskningsstipendier - Blodcancerfonden
Blodcancerfonden delar årligen ut forskningsstipendier till personer verksamma inom området hematologi. Forskningen som vi finansierar avser utvecklingsarbete som syftar till förbättring av vårdens kvalitet och patienternas livskvalitet. Medel från Blodcancerfonden har tidigare möjliggjort finansiering av många olika typer av projekt, såsom forskning inom omvårdnad, grundforskning, translationell forskning samt kliniska studier inom blodcancerområdet.
För årets utdelningsprocess lägger vi mycket stor vikt vid den populärvetenskapliga sammanfattningen av forskningsprojektet, som på ett utförligt men lättillgängligt sätt ska beskriva syftet med projektet samt vilken patientnytta som projektet förväntas leda till. Samtliga projektet som beviljas anslag kommer att tilldelas en patientrepresentant från projektet Patientpanelen som ska samarbeta med forskarna under projektets gång. Patientrepresentanterna kommer bland annat även att delta vid prioritering av vilka forskningsansökningar som ska beviljas finansiering. Därför ber vi sökande att lägga ett stort fokus på att projektets populärvetenskapliga sammanfattning är lätt att förstå, då den utgör det främsta underlaget för patientrepresentanternas granskning.
Vid frågor kontakta: Olina Lind, Medicinskt sakkunnig och forskningsansvarig på Blodcancerförbundet olina@blodcancerforbundet.se
Closing date: 15 October 2022
SCIFs pris 2022
Föreningen Sveriges Centralförening för idrottens främjande (SCIF) bildades 1867 med syftet att främja svensk idrott. Bland annat bidrog SCIF till att bygga Stockholms stadion till de olympiska spelen 1912. Idag främjar föreningen svensk idrott på olika sätt. Årligen delas två forskarpriser ut till förtjänta forskare på idrottens område. Föreningens stora pris delas ut till en erfaren senior forskare och föreningens lilla pris delas ut till yngre lovande forskare.
Europeiska anslag
ERC Starting Grant (ERC-2023-StG)
The ERC Starting Grants are designed to support excellent Principal Investigators at the career stage at which they are starting their own independent research team or programme. Applicants must have successfully defended their first PhD at least 2 and up to 7 years prior to 1 January 2023, with exceptions for parental leave, national service, clinical training and long-term illness. Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal.
Deadline: 25 October 2022
ERC Synergy Grants (ERC-2023-SyG)
The call for applications for ERC Synergy Grants 2023 is now open and will close on 8th November 2022. These are very competitive grants, and preparations for applying should be made well in advance. Please contact Tamsin Lindström at KI Grants Office if you are interested in applying for an ERC Synergy Grant.
What proposals are eligible?
Applications can be made in any field of research but must demonstrate that the proposed research cannot be carried out by a single PI working alone. Synergy projects should enable substantial advances at the frontiers of knowledge, stemming, for example, from the cross-fertilisation of scientific fields, from new productive lines of enquiry, or new methods and techniques, including unconventional approaches and investigations at the interface between established disciplines. Proposals will be evaluated on the sole criterion of scientific excellence, including outstanding synergy. These are very competitive grants. Please consult the ERC Synergy project summaries and the ERC’s mapping of funded ERC Synergy projects.
Who can apply?
ERC Synergy Grants fund small groups of two to four PIs working in an integrated fashion to bring together different skills and resources to tackle ambitious research problems. PIs must present an early achievement track-record or a ten-year track-record, whichever is most appropriate (please consult the lists of ERC Synergy grantees). One PI per 'Synergy Grant group' at any one time can be hosted or engaged by an institution outside of the EU or Associated Countries. If you or a co-applicant has an ongoing ERC Grant, please contact Tamsin Lindström at KI Grants Office to discuss applicant eligibility.
How much?
Synergy Grants can be up to a maximum of € 10 million for a period of 6 years. An additional € 4 million can be requested under certain circumstances.
Research grants, Cure Parkinson’s Trust, GB
The Cure Parkinson’s Trust invites applications for its research grants. These support laboratory or clinical research projects that have the potential to cure Parkinson’s disease. Applications must be for research that slows, stops or reverses underlying disease progression. Priority is given to research which has potential to translate into the clinic within five years.
Applications are invited world wide.
Grants are worth up to £250,000 each.
Deadline: 29 September 2022
EACVI research grants, European Society of Cardiology, EUR
The European Society of Cardiology’s European Association of Cardiovascluar Imaging (EACVI) invites applications for its research grants. These support research in the field of non-invasive imaging modalities in order to help young candidates obtain research experience in a high standard academic centre in an ESC member country other than their own.
Applicants must be silver members of the EACVI, under 40 years of age and citizens or residents of a European Society of Cardiology member country or affiliated member country. Applicants must be medical graduates at any stage in their career who have not yet obtained a permanent senior staff or consultant position or research experience above junior investigator level.
Grants are worth €30,000 over one year.
Deadline: 30 September 2022
Fight kids cancer programme, Imagine for Margo – Children without Cancer, FR and other funders
Imagine for Margo – Children without Cancer, KickCancer, the European Science Foundation, the Foundation for Children with Cancer (FKK) and the Italian National Federation of Associations of Parents of Children and Adolescents with Cancer or Leukaemia (FIAGOP) invite applications for their fight kids cancer programme. This aims to catalyse and support pan-European innovative and relevant research initiatives in paediatric cancer. Projects should aim to develop new therapies that improve the outcome for all children and adolescents with cancer. There are two categories of projects: early phase clinical trials conducted in at least two countries, and translation research projects to identify novel mechanisms of action and targets that may result in innovative new therapies or better models of disease. Pre-clinical projects including high-risk/high return proposals, or projects that leverage and advance paediatric tumour models, will be considered. Multi-disciplinary or multi-institution collaborations are strongly encouraged.
The lead institution must be an eligible research organisation located in an eligible country. Other project partners can be from related fields of expertise, provided they operate as not-for-profit. Partners from countries not listed as eligible are permitted, provided they are not delivering a core component of the project upon which major activities are dependent; such partners should plan to leverage complementary funding.
The total budget is €4 million. Early phase clinical trial grants are worth up to €1.5m per project for three years, while translational research project grants are worth up to €500,000 per project for two years.
Deadline: 3 October 2022
Research grant initiative, European Society for Paediatric Gastroenterology, Hepatology and Nutrition, EUR
The European Society for Paediatric Gastroenterology, Hepatology and Nutrition invites applications for its research grant initiative. This supports research into all aspects of gastroenterology, hepatology and nutrition.
Any ESPGHAN member is eligible to apply. Young investigators are particularly encouraged to apply.
Up to five awards worth up to €100,000 each are available for a maximum duration of 24 months.
Deadline: 4th of October 2022.
51st Fondation ARC Leopold Griffuel awards
Fondation ARC for Cancer Research launches its call for applications for the 51St Fondation ARC Léopold Griffuel Award.
With an amount of €150,000 per award, the Fondation ARC Léopold Griffuel Award is one of the most important prizes in the field of cancer research in Europe. It has been created in accordance with the will of the late Mrs. Griffuel by bequest, in honor and memory of her late husband, Mr. Léopold Griffuel. Since 1970, it has rewarded 60 scientists all over the world that have brought an important contribution to better understand, diagnose, cure and prevent cancers.
This award aims to promote scientific excellence and encourage further scientific projects in all areas of cancer, from basic to translational and clinical research.
Two prize categories can be awarded per year:
Basic Research Award
And
Clinical & Translational Award.
The application file must be submitted before October 3rd, 2022.
You can find all information needed, including the prize rules and regulations, on our website.
Please feel free to widely disseminate this call for applications to the Research Community.
Amerikanska anslag
Federal Funding agencies
Research grant, DoD Funding Opportunities for Peer Reviewed Cancer Research Program (PRCRP): Department of Defense
The goal of the PRCRP is to improve quality of life by decreasing the impact of cancer on active-duty Service Members, their families, Veterans, and the American public. To be considered for funding, applications for the FY22 PRCRP Behavioral Health Science Award must address at least one of the congressionally directed FY22 PRCRP Topic Areas. The FY22 PRCRP Topic Areas are: bladder cancer, blood cancers, brain cancer, colorectal cancer, endometrial cancer, esophageal cancer, germ cell cancers, head and neck cancer, liver cancer, lymphoma, mesothelioma, metastatic cancers, myeloma, neuroblastoma, pediatric/adolescent/young adult cancers, pediatric brain tumors, stomach cancer, sarcoma, thyroid cancer, Von Hippel-Lindau syndrome malignancies (excluding cancers of the kidney and pancreas).
Research applications in the areas of breast, kidney, lung, pancreatic, prostate, ovarian, rare cancer, or melanoma are prohibited and will be rejected. Applicants are directed to apply to the individual CDMRP cancer programs those disease areas.
Deadlines: Behavioral Health Science Award; Career Development Award (Scholar Option) – LOI due 28th September, 2022 (5:00pm, ET); Full proposal due 19th October, 2022 (11:59pm, ET).
HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed): NIH
This funding opportunity announcement (FOA) supports research to develop, characterize, and rigorously validate non-rodent mammalian models of pain, associated outcome measures and/or endpoints that will significantly advance translational research for effective pain management. These models are expected to recapitulate molecular, cellular, pathological, behavioral, and/or cognitive aspects of human pain disorders and conditions. Research supported under this FOA is expected to provide well-validated models and measures that facilitate the development of non-opioid analgesic therapeutic interventions. This FOA is not specific for any one or group of pain conditions. To be considered responsive to this FOA, applications must address at least one of the following areas:
- Development, characterization, and validation of non-rodent mammalian models of pain indications/conditions and/or pain associated with diseases. This includes validation of existing non-rodent mammalian models of pain that have not been well-validated and/or validation of existing models of pathologies or diseases, in the context of pain.
- Development and validation of pain-associated outcome measures and endpoints in non-rodent mammalian models.
Deadline: November 4, 2022. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-NS-22-070 (RO1)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required): NIH
Through the NIH Exploratory/Developmental Research Grant Program, the NIH seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to substantially advance biomedical, behavioral, and clinical research.
This program is intended to encourage new exploratory and developmental research projects. For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
Applications for Exploratory/Developmental Research Grant awards should include projects distinct from those supported through the traditional R01 activity code. For example, long-term projects, or projects designed to increase knowledge in a well-established area, are not appropriate for this FOA. Applications submitted to this FOA should be exploratory and novel. These studies should break new ground or extend previous discoveries toward new directions or applications.
Deadline: Standard dates apply. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PA-20-196 (R21)
NIH Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed): NIH
The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g., cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.
Deadline: October 16, 2022. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-22-106 (R03)
Foundations
Established Investigator grant, National Scleroderma Foundation, US
The National Scleroderma Foundation seeks applications from promising established investigators both inside and outside the field of scleroderma research who wish to propose pilot studies to obtain preliminary data dealing with a highly innovative and/or highly relevant theme related to the disease. This grant will support pilot research that is likely to lead to more substantial unlimited research project grants from federal or non-federal sources.
Eligibility: Applicants must have a doctorate degree in Medicine, Osteopathy, Veterinary Medicine or one of the sciences; must have completed a postdoctoral fellowship; and have been principal investigator on grants from the National Scleroderma Foundation or other national, private or government agencies in the past.
Budget: The Established Investigator Award is a two-year award in the amount of $200,000 total. Applicants may request up to $100,000 per year (this amount is to include budgeted indirect costs) for up to two years, with the total award not to exceed $200,000. A maximum of 8% of the proposed yearly budget may be allocated to indirect costs.
Deadline: 15th September 2022. 5pm ET.
Further info: Scleroderma - Grant opportunities and Scleroderma - application form
Research grants, Standard Awards and Post-doctoral Fellowship Awards, BrightFocus Foundation, US
Alzheimer’s Disease Research. BrightFocus provides research funds for U.S. domestic as well as international researchers pursuing pioneering research leading to greater understanding, prevention, and treatment of Alzheimer's disease. The ADR program offers two types of awards:
Standard Award: the standard award provides significant funding for researchers who have already generated some amount of preliminary data, but are often required to demonstrate additional, significant progress before they can apply to governmental or industrial funding agencies. Budget: Awards are worth USD 100,000 each per year for up to three years. Indirect costs are not covered by this grant. Eligibility: Applicants should have completed their formal post-doctoral mentored research training and must be the intellectual and creative leads for the proposed projects.
Postdoctoral Fellowship Award: Postdoctoral fellowship awards are intended for young researchers in their final stages of mentored training. These awards fund projects in an established laboratory that will serve as the basis for the applicant's own independent research career. Budget: Awards are worth USD 100,000 each per year for up to two years. Indirect costs are not covered by this grant. Eligibility: Postdoctoral Fellowships are available to junior and senior postdoctoral fellows, who are within 5 years of doctoral degree conferral (or the end of their residency). Applicants with pending appointments are eligible to apply, but the appointment must be finalized by the start of the award. The proposal should be initiated by the postdoctoral fellow and not the supervisor.
Deadline (both grants): 1st November, 2022.
National Glaucoma Research. BrightFocus provides research funds for U.S. and international researchers pursuing pioneering research leading to greater understanding, prevention, and treatment of glaucoma. The NGR program offers two types of awards:
Standard Award: the standard award provides significant funding for researchers who have already generated some amount of preliminary data, but are often required to demonstrate additional, significant progress before they can apply to governmental or industrial funding agencies. Budget: Awards are worth USD 100,000 each per year for up to two years. Indirect costs are not covered by this grant. Eligibility: Applicants should have completed their formal post-doctoral mentored research training and must be the intellectual and creative leads for the proposed projects.
Postdoctoral Fellowship Award: Postdoctoral fellowship awards are intended for young researchers in their final stages of mentored training. These awards fund projects in an established laboratory that will serve as the basis for the applicant's own independent research career. Budget: Awards are worth USD 75,000 each per year for up to two years. Indirect costs are not covered by this grant. Eligibility: Postdoctoral Fellowships are available to junior and senior postdoctoral fellows, who are within 5 years of doctoral degree conferral (or the end of their residency). Applicants with pending appointments are eligible to apply, but the appointment must be finalized by the start of the award. The proposal should be initiated by the postdoctoral fellow and not the supervisor.
Deadline (both grants): 25th October, 2022.
Research grant, Circuits & Cellular Targets for Parkinson’s Symptoms – Pre-clinical Program, Michael J Fox Foundation, US
The Michael J Fox Foundation invites applications for its circuits and cellular targets for Parkinson’s symptoms – pre-clinical program. This program seeks to further our understanding of the pathophysiological mechanisms that contribute to Parkinson’s disease with pre-clinical models. It also aims to identify the specific links between brain regions, cell types and signaling pathways to behavioral endpoints related to motor and non-motor symptoms of Parkinson’s disease (PD). Funding will support projects that aim to:
- Characterize the emergence, time course, progression and severity of behavioral symptoms.
- Identify and manipulate neural circuits whose activity underlies or modifies behavioral symptoms.
- Identify cell types, neurotransmitter and neuromodulator receptors, or intracellular signaling pathways that are enriched in the brain regions and neural circuits contributing to behavioral symptoms.
- Test pre-clinical therapeutic interventions to ameliorate behavioral symptoms.
The Circuits & Cellular Targets for Parkinson’s Symptoms – Pre-clinical Program supports projects proposing to use a variety of animal models of Parkinson’s disease, including:
- Mouse, rat, and non-human primate systems.
- Genetic, toxin, lesion, or protein aggregation-based models of Parkinson’s disease.
Eligibility: Applications may be submitted by all researchers or clinicians. Post-doctoral fellows are eligible to apply as co-investigators with the designation of an administrative primary investigator who directs the laboratory in which the fellow will conduct research. Training or mentoring-only proposals will not be considered. Budget: $250,000 – $500,00 for studies primarily employing rodent model systems. Projects intending to use non-human primate model systems may request up to $1,000,000. A maximum of 15% of the proposed yearly budget may be allocated to indirect costs.
Deadline: Pre-proposals – 27th September 2022, 5pm ET. Full application (by invite only) – 12th January 2023, 5pm ET.